Number of items: 39.
2023
Murphy, M., McCaughan, E., Thompson, G., Carson, M. A., Hanna, J. R., Donovan, M., Wilson, R. H. and Fitzsimons, D.
(2023)
Trusting relationships between patients with non-curative cancer and healthcare professionals create ethical obstacles for informed consent in clinical trials: a grounded theory study.
BMC Palliative Care, 22,
85.
(doi: 10.1186/s12904-023-01204-6)
(PMID:37393250)
(PMCID:PMC10315048)
2022
El Helali, A. et al.
(2022)
A first-in-human Phase I dose-escalation trial of the novel therapeutic peptide, ALM201, demonstrates a favourable safety profile in unselected patients with ovarian cancer and other advanced solid tumours.
British Journal of Cancer, 127(1),
pp. 92-101.
(doi: 10.1038/s41416-022-01780-z)
(PMID:35568736)
Brown, L. C. et al.
(2022)
Experiences of running a stratified medicine adaptive platform trial: Challenges and lessons learned from 10 years of the FOCUS4 trial in metastatic colorectal cancer.
Clinical Trials, 19(2),
pp. 146-157.
(doi: 10.1177/17407745211069879)
(PMID:35083924)
(PMCID:PMC9036145)
2021
Adams, R. A. et al.
(2021)
Capecitabine versus active monitoring in stable or responding metastatic colorectal cancer after 16 weeks of first-line therapy: results of the randomized FOCUS4-N trial.
Journal of Clinical Oncology, 39(33),
pp. 3693-3704.
(doi: 10.1200/JCO.21.01436)
(PMID:34516759)
Hanna, C. R. , Boyd, K. A. , Wincenciak, J. , Graham, J., Iveson, T., Jones, R. J. and Wilson, R.
(2021)
Do clinical trials change practice? A longitudinal, international assessment of colorectal cancer prescribing practices.
Cancer Treatment and Research Communications, 28,
100445.
(doi: 10.1016/j.ctarc.2021.100445)
(PMID:34425469)
2019
Joharatnam-Hogan, N. et al.
(2019)
Aspirin as an adjuvant treatment for cancer: feasibility results from the Add-Aspirin randomised trial.
Lancet Gastroenterology and Hepatology, 4(11),
pp. 854-862.
(doi: 10.1016/S2468-1253(19)30289-4)
(PMID:31477558)
Salvucci, M. et al.
(2019)
A machine learning platform to optimize the translation of personalized network models to the clinic.
JCO Clinical Cancer Informatics(3),
pp. 1-17.
(doi: 10.1200/CCI.18.00056)
(PMID:30995124)
2018
Arkenau, H.-T. et al.
(2018)
An extended phase Ib study of epertinib, an orally active reversible dual EGFR/HER2 tyrosine kinase inhibitor, in patients with solid tumours.
European Journal of Cancer, 103,
pp. 17-23.
(doi: 10.1016/j.ejca.2018.07.134)
(PMID:30196106)
Basu, B. et al.
(2018)
Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer.
Annals of Oncology, 29(9),
pp. 1918-1925.
(doi: 10.1093/annonc/mdy245)
(PMID:30016392)
(PMCID:PMC6158767)
Cross, W. et al.
(2018)
The evolutionary landscape of colorectal tumorigenesis.
Nature Ecology and Evolution, 2(10),
pp. 1661-1672.
(doi: 10.1038/s41559-018-0642-z)
(PMID:30177804)
(PMCID:PMC6152905)
Allen, W. L. et al.
(2018)
Transcriptional subtyping and CD8 immunohistochemistry identifies patients with stage II and III colorectal cancer with poor prognosis who benefit from adjuvant chemotherapy.
JCO Precision Oncology(2),
pp. 1-15.
(doi: 10.1200/PO.17.00241)
(PMID:30088816)
(PMCID:PMC6040635)
Woodcock, V. K. et al.
(2018)
A first-in-human phase I study to determine the maximum tolerated dose of the oral Src/ABL inhibitor AZD0424.
British Journal of Cancer, 118(6),
pp. 770-776.
(doi: 10.1038/bjc.2017.484)
(PMID:29438361)
(PMCID:PMC5877436)
Adams, R. et al.
(2018)
Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS , and NRAS (FOCUS4-D): a phase 2–3 randomised trial.
Lancet Gastroenterology and Hepatology, 3(3),
pp. 162-171.
(doi: 10.1016/S2468-1253(17)30394-1)
(PMID:29254887)
(PMCID:PMC6125825)
2017
Lawler, M. et al.
(2017)
Critical research gaps and recommendations to inform research prioritisation for more effective prevention and improved outcomes in colorectal cancer.
Gut, 67(1),
pp. 179-193.
(doi: 10.1136/gutjnl-2017-315333)
(PMID:29233930)
(PMCID:PMC5754857)
Lindner, A. U. et al.
(2017)
BCL-2 system analysis identifies high-risk colorectal cancer patients.
Gut, 66(12),
pp. 2141-2148.
(doi: 10.1136/gutjnl-2016-312287)
(PMID:27663504)
Schrock, A. B. et al.
(2017)
Genomic profiling of small-bowel adenocarcinoma.
JAMA Oncology, 3(11),
p. 1546.
(doi: 10.1001/jamaoncol.2017.1051)
(PMID:28617917)
(PMCID:PMC5710195)
Alvi, M. A., Wilson, R. H. and Salto-Tellez, M.
(2017)
Rare cancers: the greatest inequality in cancer research and oncology treatment.
British Journal of Cancer, 117(9),
pp. 1255-1257.
(doi: 10.1038/bjc.2017.321)
(PMID:28934760)
(PMCID:PMC5672935)
Alderdice, M. et al.
(2017)
Natural killer-like signature observed post therapy in locally advanced rectal cancer is a determinant of pathological response and improved survival.
Modern Pathology, 30(9),
pp. 1287-1298.
(doi: 10.1038/modpathol.2017.47)
(PMID:28621318)
Alvi, M. A. et al.
(2017)
Molecular profiling of signet ring cell colorectal cancer provides a strong rationale for genomic targeted and immune checkpoint inhibitor therapies.
British Journal of Cancer, 117(2),
pp. 203-209.
(doi: 10.1038/bjc.2017.168)
(PMID:28595259)
(PMCID:PMC5520517)
Salvucci, M. et al.
(2017)
A stepwise integrated approach to personalized risk predictions in stage III colorectal cancer.
Clinical Cancer Research, 23(5),
pp. 1200-1212.
(doi: 10.1158/1078-0432.CCR-16-1084)
(PMID:27649552)
2016
Coyle, C. et al.
(2016)
ADD-ASPIRIN: A phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours.
Contemporary Clinical Trials, 51,
pp. 56-64.
(doi: 10.1016/j.cct.2016.10.004)
(PMID:27777129)
(PMCID:PMC5127874)
Jamieson, D. et al.
(2016)
A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours.
European Journal of Cancer, 68,
pp. 1-10.
(doi: 10.1016/j.ejca.2016.08.026)
(PMID:27693888)
Graham, D. M., Coyle, V. M., Kennedy, R. D. and Wilson, R. H.
(2016)
Molecular subtypes and personalized therapy in metastatic colorectal cancer.
Current Colorectal Cancer Reports, 12(3),
pp. 141-150.
(doi: 10.1007/s11888-016-0312-y)
(PMID:27340376)
(PMCID:PMC4879165)
ORIGIN Trial Investigators,
(2016)
Cardiovascular and other outcomes postintervention with insulin glargine and omega-3 fatty acids (ORIGINALE).
Diabetes Care, 39(5),
pp. 709-716.
(doi: 10.2337/dc15-1676)
(PMID:26681720)
Lawler, M. et al.
(2016)
Delivering a research-enabled multistakeholder partnership for enhanced patient care at a population level: The Northern Ireland Comprehensive Cancer Program.
Cancer, 122(5),
pp. 664-673.
(doi: 10.1002/cncr.29814)
(PMID:26695702)
(PMCID:PMC4864440)
Pitsiladis, Y. P. et al.
(2016)
Athlome Project Consortium: a concerted effort to discover genomic and other “omic” markers of athletic performance.
Physiological Genomics, 48(3),
pp. 183-190.
(doi: 10.1152/physiolgenomics.00105.2015)
(PMID:26715623)
(PMCID:PMC4773890)
Dunne, P.D. et al.
(2016)
EphA2 expression is a key driver of migration and invasion and a poor prognostic marker in colorectal cancer.
Clinical Cancer Research, 22(1),
pp. 230-242.
(doi: 10.1158/1078-0432.CCR-15-0603)
(PMID:26283684)
(PMCID:PMC4694030)
2015
Lawler, M., Kaplan, R., Wilson, R.H. and Maughan, T.
(2015)
Changing the paradigm - multistage multiarm randomized trials and stratified cancer medicine.
Oncologist, 20(8),
pp. 849-851.
(doi: 10.1634/theoncologist.2015-0014)
(PMID:26070918)
(PMCID:PMC4524758)
Alvi, M. A. et al.
(2015)
Comprehensive molecular pathology analysis of small bowel adenocarcinoma reveals novel targets with potential for clinical utility.
Oncotarget, 6(25),
pp. 20863-20874.
(doi: 10.18632/oncotarget.4576)
(PMID:26315110)
(PMCID:PMC4673235)
Graham, D.M., Turkington, R.C., Salto-Tellez, M., Coyle, V.M. and Wilson, R.H.
(2015)
RE: Test of four colon cancer risk-scores in formalin fixed paraffin embedded microarray gene expression data.
Journal of the National Cancer Institute, 107(5),
djv055.
(doi: 10.1093/jnci/djv055)
(PMID:25758031)
Bogaerts, J. et al.
(2015)
Clinical trial designs for rare diseases: studies developed and discussed by the international rare cancers initiative.
European Journal of Cancer, 51(3),
pp. 271-281.
(doi: 10.1016/j.ejca.2014.10.027)
(PMID:25542058)
Wardle, S. L., Bailey, M. E. , Kilikevicius, A., Malkova, D. , Wilson, R. H. , Venckunas, T. and Moran, C.
(2015)
Plasma microRNA levels differ between endurance and strength athletes.
PLoS ONE, 10(4),
e0122107.
(doi: 10.1371/journal.pone.0122107)
(PMID:25881132)
(PMCID:PMC4400105)
2014
Moreno Garcia, V. et al.
(2014)
Dose-response relationship in phase I clinical trials: a European Drug Development Network (EDDN) collaboration study.
Clinical Cancer Research, 20(22),
pp. 5663-5671.
(doi: 10.1158/1078-0432.CCR-14-0719)
Andreyev, J. et al.
(2014)
Guidance on the management of diarrhoea during cancer chemotherapy.
Lancet Oncology, 15(10),
e447-e460.
(doi: 10.1016/S1470-2045(14)70006-3)
(PMID:25186048)
Wasan, H. et al.
(2014)
Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial.
Lancet Oncology, 15(6),
pp. 631-639.
(doi: 10.1016/S1470-2045(14)70106-8)
(PMID:24703531)
(PMCID:PMC4012566)
Maughan, T.S. et al.
(2014)
A feasibility study testing four hypotheses with phase II outcomes in advanced colorectal cancer (MRC FOCUS3): a model for randomised controlled trials in the era of personalised medicine?
British Journal of Cancer, 110(9),
pp. 2178-2186.
(doi: 10.1038/bjc.2014.182)
(PMID:24743706)
(PMCID:PMC4007241)
Turkington, R.C., Purcell, C., James, C.R., Millar, J., Napier, E., Law, D., Gallagher, R., Morris, M., Wilson, R.H. and Eatock, M.M.
(2014)
A phase I trial of bortezomib in combination with epirubicin, carboplatin and capecitabine (ECarboX) in advanced oesophagogastric adenocarcinoma.
Investigational New Drugs, 32(2),
pp. 250-260.
(doi: 10.1007/s10637-013-9970-7)
(PMID:23665866)
Glasspool, R.M. et al.
(2014)
A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer.
British Journal of Cancer, 110(8),
pp. 1923-1929.
(doi: 10.1038/bjc.2014.116)
Jones, C., Badger, S. A., Stevenson, M., Diamond, T., McKie, L. D., Taylor, M. A., Wilson, R. H. and Lynch, T. B.
(2014)
PET-CT as a predictor of outcome in resectable colorectal liver metastases.
European Journal of Gastroenterology and Hepatology, 26(4),
pp. 466-472.
(doi: 10.1097/MEG.0000000000000036)
(PMID:24445726)
This list was generated on Mon Sep 9 05:00:26 2024 BST.